TGTX
Tg TherapeuticsยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
TGTX Profile
Tg Therapeutics, Inc.
A biopharmaceutical company that develops therapeutics for diseases caused by protien or gene dysfunction
3020 Carrington Mill Blvd, Suite 475, Morrisville, North Carolina 27560
--
TG Therapeutics, Inc., was founded in Delaware in 1993. The company is a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development and commercialization of new therapies for B-cell diseases. In addition to a series of studies including several investigational drugs, TG has received BRIUMVI (ublituximab-xiiy) approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with recurrent multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.
